Sugi Predict

Sugi Predict / Compounds / SCHEMBL265135

SCHEMBL265135

SCHEMBL265135

C[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.61
▸ TBXAS1 P24557 2/20 0.60
▸ HPGD P15428 1/20 0.59
▸ CYP3A4 P08684 2/20 0.58
▸ TSHR P16473 1/20 0.58
▸ ALPI P09923 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ PTGS1 P23219 1/20 0.57
▸ XIAP P98170 1/20 0.57
▸ SLC7A5 Q01650 1/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ MAPK1 P28482 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.54
▸ CPA1 P15085 2/20 0.53
▸ CPA3 P15088 2/20 0.53
▸ FOLH1 Q04609 1/20 0.53
▸ CPB1 P15086 1/20 0.53
▸ CPB2 Q96IY4 1/20 0.53
▸ MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265577 1.00 CYP1A2 (0.61) CYP1A2TBXAS1HPGDCYP3A4TSHR
SCHEMBL65930 1.00 CYP1A2 (0.61) CYP1A2TBXAS1HPGDCYP3A4TSHR
SCHEMBL27514358 0.98 CYP1A2 (0.59) CYP1A2TBXAS1HPGDCYP3A4TSHR
Water SCHEMBL10936876 0.98 CYP1A2 (0.59) CYP1A2TBXAS1HPGDCYP3A4TSHR
SCHEMBL11237591 0.91 TBXAS1 (0.59) CYP1A2TBXAS1HPGDCYP3A4TSHR
Tert-Butylamine SCHEMBL1883188 0.90 ALPI (0.53) CYP1A2TBXAS1HPGDCYP3A4TSHR
Tert-Butylamine SCHEMBL1880992 0.90 ALPI (0.53) CYP1A2TBXAS1HPGDCYP3A4TSHR
Tert-Butylamine SCHEMBL1880991 0.90 ALPI (0.53) CYP1A2TBXAS1HPGDCYP3A4TSHR
SCHEMBL7507834 0.88 MME (0.63) CPA1
SCHEMBL16948243 0.88 MME (0.63) CPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES THE BROAD INSTITUTE, INC. 2024-01-25 — — US disclosed
US-20240024410-A1 THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS THE JOHNS HOPKINS UNIVERSITY 2024-01-25 — — US disclosed
WO-2024005461-A1 NOVEL LINKER COMPOUND AND LIGAND-DRUG CONJUGATE THEREFOR 주식회사 트리오어 2024-01-04 — — WO disclosed
WO-2024005460-A1 COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME 주식회사 트리오어 2024-01-04 — — WO disclosed
US-20230317700-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-10-05 — — US disclosed
WO-2023178641-A1 DNA TOXIC DIMER COMPOUND AND CONJUGATE THEREOF 成都百利多特生物药业有限责任公司 2023-09-28 — — WO disclosed
EP-4227309-A1 DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF Sichuan Baili Pharmaceutical Co. Ltd. (CN) 2023-08-16 — — EP disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 — — US disclosed
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-11708391-B2 Rapaglutins, novel inhibitors of GLUT and use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-25 — — US disclosed
WO-1994019349-A1 XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-09-01 — — WO disclosed
EP-0449175-A2 Selective adenosine receptor agents MERRELL PHARMACEUTICALS INC. (US) 1991-10-02 — — EP disclosed
US-5047534-A Xanthine derivatives; hyupotensive agents, cardiotonic agents MERRELL DOW PHARMACEUTICALS INC. (US) 1991-09-10 — — US disclosed
US-4826815-A HYPOTENSIVE ABBOTT LABORATORIES (US) 1989-05-02 — — US disclosed
US-4652551-A PEPTIDE, HYPOTENSIVE ABBOTT LABORATORIES (US) 1987-03-24 — — US disclosed
US-4645759-A HYPOTENSIVE AGENTS ABBOTT LABORATORIES (US) 1987-02-24 — — US disclosed
EP-0099517-B1 PROCESS FOR CARRYING OUT ELECTROMICROBIAL REDUCTIONS BASF Aktiengesellschaft (DE) 1986-11-26 — — EP disclosed
EP-0172346-A2 Renin inhibiting compounds ABBOTT LABORATORIES (US) 1986-02-26 — — EP disclosed
EP-0172347-A2 Renin inhibiting compounds ABBOTT LABORATORIES (US) 1986-02-26 — — EP disclosed
US-4464235-A Carrying out electromicrobial reductions BASF AKTIENGESELLSCHAFT (DE) 1984-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708391-B2 Rapaglutins, novel inhibitors of GLUT and use thereof SLC2A1, SLC2A4, SLC2A2 CYP1A2 3807/4885TBXAS1 1014/4885HPGD 3458/4885
US-20240024410-A1 THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS MRPS23, CD2BP2, MRPL21 CYP1A2 4720/4885TBXAS1 2417/4885HPGD 2326/4885
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP CYP1A2 3960/4885TBXAS1 3469/4885HPGD 1863/4885
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES COASY, JMJD7, PTMS CYP1A2 2469/4885TBXAS1 1685/4885HPGD 2020/4885
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP CYP1A2 387/4885TBXAS1 840/4885HPGD 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.